Mkt Cap$2.30T+3.75%
24h Vol$73.13B
BTC Dom56.3%
ETH Dom9.8%
F&G22Extreme Fear
BTC$64,497.00+3.82% ETH$1,871.61+6.03% USDT$0.9994+0.03% BNB$579.05+2.39% USDC$0.9999+0.01% XRP$1.10+4.16% SOL$77.14+3.50% TRX$0.3252+0.23% FIGR_HELOC$1.04+0.37% HYPE$65.52+3.83% DOGE$0.0741+3.47% USDS$0.9998+0.02% RAIN$0.0149+3.83% ZEC$542.40+10.43% LEO$9.68+1.65% WBT$56.37+3.41% BTC$64,497.00+3.82% ETH$1,871.61+6.03% USDT$0.9994+0.03% BNB$579.05+2.39% USDC$0.9999+0.01% XRP$1.10+4.16% SOL$77.14+3.50% TRX$0.3252+0.23% FIGR_HELOC$1.04+0.37% HYPE$65.52+3.83% DOGE$0.0741+3.47% USDS$0.9998+0.02% RAIN$0.0149+3.83% ZEC$542.40+10.43% LEO$9.68+1.65% WBT$56.37+3.41%
News

RLMD

Total Stories
1
Section
RLMD
Why Is Relmada Therapeutics (RLMD) Stock Up Today? NDV-01 Trial Update and $160M PIPE Deal
Market Analysis

Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal

Relmada Therapeutics stock surged after reporting positive Phase 2 trial results for NDV-01 and announcing a $160 million PIPE financing.

Tim FriesMar 9, 20264 min read